NEW YORK (GenomeWeb) – Amoy Diagnostics today announced a deal with biopharmaceutical firm Canbridge Life Sciences to develop a companion diagnostic for Canbridge's lead product, CAN008.

Amoy will supply its CD95 IHC and CpG2 qPCR kits as part of the deal. CAN008 is a fully human Fc fusion protein, and in a previous Phase II trial conducted in Europe, it demonstrated "significant overall survival benefit" for recurrent glioblastoma multiforme patients with high expression of the CD95 ligand, or low methylation of CD95L promotor CpG2, the companies said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.